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Abstract: In ovarian cancer, multiple attempts to adjust the standard taxane/platinum doublet by adding
cytotoxic therapy or varying scheduling, dosage, and delivery have been met with limited success. Alternative
methods to improve the grim prognosis of ovarian cancer, including molecular therapies, are currently under
investigation. Efforts have been made to study tyrosine kinase inhibitors (including imatinib and pazopanib),
Src kinase inhibitors and histone deacetylase inhibitors (HDACi) in combination with taxanes/platinums
in order to improve efficacy. Unfortunately, while many pre-clinical and early phase clinical trials argue
that the utilization of these molecular targets may enhance survival, only modest benefit has been seen in
larger clinical trials. Other agents that have been evaluated include proteasome inhibitors, folate receptor
antagonists, MEK inhibitors and opiate antagonists. In this review, we discuss the mechanisms of these
targeted therapies and highlight the current and ongoing clinical trials that utilize these targeted agents in
combination with taxanes and platinums in advanced ovarian cancer.
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Introduction
Ovarian cancer is the fifth leading cause of cancer death
in women in the United States with a 5-year survival of
only 30% in patients with advanced stage disease (1,2). For
more than a decade, the standard treatment for advanced
ovarian cancer has been optimal surgical debulking
followed by a paclitaxel/platinum regimen. Attempts to
improve on outcomes by adding cytotoxic therapies have
only resulted in increased toxicity without significant
benefit (3-7). Other pursuits such as intraperitoneal
(IP) drug delivery, optimization of the platinum/taxane
schedule, and consolidation with anti-angiogenic drugs,
such as bevacizumab, or with poly-ADP-ribose polymerase
(PARP) inhibitors, have been met with limited success
and often increased toxicity (8-13). Given ovarian cancer’s
lethality, yet elusiveness to current treatments, the need for
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expanded, targeted therapies for this disease is crucial. This
review will focus on various emerging molecular targets and
therapeutic options that are being explored in combination
with taxanes and platinums, including selective and multitargeted tyrosine kinase inhibitors, Src kinase inhibitors,
and histone deacetylase inhibitors (HDACi).
Tyrosine kinase inhibitors
With imatinib revolutionizing the treatment of chronic
myelogenous leukemia (CML) in the late 1990s, interest and
research dedicated to investigate its utility in solid tumors
ensued (14). Imatinib is a tyrosine kinase inhibitor, which is
specific for the ABL domain, c-KIT, and the platelet-derived
growth factor receptor (PDGFR). Its mechanism of action
prompted exploring its role in ovarian cancer (15). Of note,
platelet derived growth factor (PDGF) and PDGFR-alpha (α)
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have poor prognostic value in ovarian cancer and PDGFR is
active in tumor-associated endothelial cells and presumably
contributes to tumor angiogenesis (16,17). This pre-clinical
data led to several clinical trials of imatinib in ovarian cancer.
Schilder et al. performed a phase II trial evaluating single agent
imatinib in patients with recurrent or persistent epithelial
ovarian or primary peritoneal carcinoma. Fifty-six patients
received imatinib 400 mg twice daily. Imatinib had minimal
activity and the median progression free survival (PFS) and
overall survival (OS) were 2 and 16 months, respectively. Nine
patients were progression free for at least 6 months, including
one patient who had a complete response (CR). Imatinib was
well tolerated; the most common grade 3 and 4 toxicities were
neutropenia, gastrointestinal, dermatologic effects, pain and
electrolyte disturbances. Biomarker analysis failed to identify
any predictive markers of imatinib activity (18). In another
phase II trial of single agent imatinib in 13 patients with
recurrent, platinum-resistant low-grade serous carcinoma of
the ovary, peritoneum, or fallopian tube, there were no CRs
or partial responses (PRs) seen. In contrast to the previous
trial, patients received imatinib 600 mg daily. The median
PFS and OS were 1.3 and 4.9 months, respectively. Imatinib
was well tolerated but again had no activity as a single agent
in this population (19). Alberts et al. conducted a phase II
trial of imatinib 400 mg daily in recurrent ovarian cancer in
patients with biomarker positive c-Kit (11%) and PDGFR
(89%). Of the 19 eligible patients, there were no objective
responses. The median OS was 10 months and notably,
32% of patients came off study within the first month due
to adverse events. Eleven percent of patients had grade 4
hematologic and 37% had grade 3 non-hematologic toxicity.
Not only did this trial show a lack of activity in patients with
imatinib specific mutations, but it also differed from the
previous two in that there were significant adverse events (20).
While imatinib has limited activity as a single agent,
a synergy between imatinib and paclitaxel has been
hypothesized. Circulating endothelial progenitors (CEP) are
mobilized after paclitaxel administration. CEPs assist tumor
cell proliferation and angiogenesis, counteracting the effects
of paclitaxel. However, imatinib dampens the CEP response
by inhibiting PDGFR and subsequently, prevents additional
tumor growth (16,21). Safra et al. evaluated intermittent
imatinib in combination with paclitaxel in 14 patients with
recurrent or persistent epithelial ovarian, fallopian tube, or
primary peritoneal carcinoma. Imatinib 300 mg twice daily
was given for 4 consecutive days each week in combination
with weekly paclitaxel at a dose of 80 mg/m2 for a median of
5.7 cycles (range <1 to 12.3). Of 12 evaluable patients, nine
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were progression free at 12 weeks, and four had a PR [two
by Response Evaluation Criteria in Solid Tumors (RECIST)
and two by CA-125]. A PFS of longer than 6 months was
seen in five patients and PFS of more than 12 months in
two patients. Toxicities included grade 3 diarrhea (resolving
after imatinib dose reduction), and two patients with grade
3 neutropenia or neutropenia/thrombocytopenia (resolving
after paclitaxel dose reduction). Although it was a small
trial, the combination was tolerable and demonstrated antitumor activity (22).
Docetaxel has also been studied in combination with
imatinib. In a phase II study conducted by Matei et al.,
23 patients with advanced, platinum-resistant or refractory
epithelial ovarian cancer and a median of 3 prior treatments
received imatinib 600 mg daily with docetaxel 30 mg/m2
weekly (weeks 1-4 of every 6-week cycle). The objective
response rate (ORR) was 21.7%. Responses included one
CR, three PRs, and three patients with stable disease (SD)
at 4 months. Most adverse effects (AEs) were grade 1 or
2 and included fatigue, nausea, diarrhea, anorexia, and
edema (23). Non-taxane agents are also being combined
with imatinib. A trial of imatinib and gemcitabine has been
completed and results are awaited (24).
Pazopanib is a multikinase inhibitor, which has multiple
targets including PDGFR and vascular endothelial growth
factor receptor (VEGFR). It has been studied in both
recurrent ovarian cancer and as maintenance therapy.
Friedlander et al. conducted a phase II trial of pazopanib
monotherapy in 36 patients with low-volume recurrent
epithelial ovarian, fallopian tube, or primary peritoneal
carcinoma. All had received initial platinum-based
chemotherapy with a complete CA-125 response. Upon
elevation of CA-125 to >2× the upper limit of normal,
patients were treated with pazopanib 800 mg daily until
progression of disease or unacceptable toxicity. ORR was
18% (95% CI, 4-43%) in patients with measurable disease
at baseline. Thirty-one percent of patients had a CA-125
response and PFS at 6 months was 17%. Twenty-eight
percent of patients experienced toxicity requiring pazopanib
discontinuation. Only one grade 4 AE was seen (peripheral
edema), but there were multiple grade 3 toxicities (56%),
which included fatigue, diarrhea, aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) elevation, and
γ-glutamyl transpeptidase (GGT) elevation (25).
More recently, the Arbeitsgemeinschaft Gynaekologische
Onkologie (AGO) studied pazopanib as maintenance
therapy for 2 years vs. placebo in 940 patients with stage IIIV ovarian, fallopian tube, or primary peritoneal carcinoma
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after initial debulking and at least five cycles of platinumtaxane chemotherapy. Patients had no evidence of disease
progression after primary therapy and were randomized
1:1 to receive pazopanib 800 mg daily or placebo for up to
24 months. The primary endpoint was PFS. Maintenance
pazopanib resulted in a significant improvement in PFS
when compared to placebo (17.9 vs. 12.3 months; HR 0.77;
95% CI, 0.64-0.91; P=0.0021). There were significantly
more AEs leading to treatment discontinuation in the
pazopanib arm (33.3%) when compared to the placebo
arm (5.6%). Grade 3/4 toxicities included hypertension,
neutropenia, liver related toxicity, diarrhea, fatigue,
thrombocytopenia, and palmar-plantar erthrodysesthesia.
Unfortunately, there was no survival benefit between
pazopanib and placebo (HR 1.08; 95% CI, 0.97-1.33;
P=0.499) (26). Additional studies of pazopanib with
topotecan, doxorubicin, cyclophosphomide, or paclitaxel in
refractory or recurrent ovarian cancer are ongoing (27-30).
Given the trials described above, future studies of pazopanib
will certainly need to balance efficacy with toxicity.
Src kinase inhibitors
Src kinase is a non-receptor tyrosine kinase that is
overexpressed and activated in late stage ovarian cancer (31).
Src activation supports vascular endothelial growth factor
A (VEGF-A) expression and inhibits transforming growth
factor beta 1 (TGFβ1), a protein that modulates cancerassociated fibroblasts in the ovarian cancer microenvironment
(32-34). In ovarian cancer models, the activation of Src
prevents microtubule assembly and stabilization, leading to
taxane resistance (35,36). In these models, inhibiting Src can
reverse the taxane resistance (37). The mechanism of the
resensitization to taxanes is unclear; however, it may be that
Src inhibition decreases the concentration of intracellular
paclitaxel required to disrupt microtubule dynamics (38).
Saracatinib (AZD0530), an oral inhibitor of Src kinase,
was shown in vitro to reduce Src phosphorylation and
prevent cell migration (39). In a phase I study done in 116
patients with multiple solid tumors, including 16% with
ovarian cancer, patients were treated with saracatinib (once
daily oral dosing from 125-300 mg) in combination with
carboplatin and/or paclitaxel. Objective responses were
seen in 5/44 of patients receiving saracatinib (125-300 mg),
carboplatin, and paclitaxel every 3 weeks; two of those were
in ovarian cancer patients. In those getting saracatinib and
paclitaxel weekly, objective responses were seen in 5/24
patients (one was ovarian) (40). This then led to a phase II/
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III study where 107 patients with platinum resistant ovarian,
fallopian, and primary peritoneal cancer were randomized
to receive weekly paclitaxel 80 mg/m 2 with or without
saracatinib 175 mg daily. There was no difference in PFS
(4.7 vs. 5.3 months; HR 1.00; 95% CI, 0.65-1.54; P=0.99)
or OS (10.1 vs. 12.3 months; HR 1.01; 95% CI, 0.56-1.58;
P=0.81). Grade 3 and 4 toxicities attributed to saracatinib
were abdominal pain and febrile neutropenia (41). Another
phase II study of saracatinib, carboplatin and paclitaxel in
advanced ovarian cancer has been completed and results are
awaited (42).
Despite the lack of efficacy thus far with saracatinib in
ovarian cancer, other Src kinase inhibitors, such as dasatinib,
have been evaluated. In a phase I dose escalation study of 20
patients, dasatinib at doses of 100, 120, or 150 mg daily, was
combined with paclitaxel 175 mg/m2 and carboplatin area
under the curve (AUC) 6 every 3 weeks. The recommended
phase II dose (RP2D) of dasatinib was determined to be 150
mg. The median PFS and OS were 7.8 months and 16.2
months, respectively (43). Dasatinib will be in investigated
in a phase II trial, GOG028, which was activated in
February 2014 (44). Given the expression of Src in clear
cell carcinoma (CCC), this clinical trial projects to enroll
ovarian CCC patients recurred after initial platinum/
taxane treatment. The patients will receive dasatinib 160
mg daily. Patients must be Wilms tumor 1 (WT1) and
estrogen receptor (ER) negative by immunohistochemistry
(IHC). The negative WT1 and ER expression are used
to differentiate clear cell from epithelial ovarian tumors.
ARID1A mutation status will be assessed in enrolled
patients (44). ARID1A is the most frequently mutated gene
in ovarian CCC, found in 46-75% of CCC. Loss of this
gene’s function is associated with a shorter PFS, worse OS,
and greater chemotherapy resistance (45). The ARID1A
gene codes for the BAF250a protein. This protein is part
of a chromatin modeling family that binds to DNA and
has roles in DNA repair (46,47). The expectation is that
those patients that have the ARID1A mutation will be
hypersensitive to dasatinib. ARID1A mutation status will be
assessed using next-generation and exon-capture sequencing
and will be tabulated to determine the correlation between
BAF250a IHC and ARID1A mutations. This will help to
identify whether IHC is predictive for better responses to
the inhibitor.
Histone deacetylase inhibitors (HDACi)
Histones are proteins composed of positively charged
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amino acids. They are bound to negatively charged DNA
and are regulators of gene expression. Modification of the
histone proteins controls gene transcription, replication,
and DNA repair. Methylation of histones turns off
gene transcription, while histone acetylation, which
occurs mostly on lysine residues, is associated with a
morphology that facilitates transcription (48). HDACi,
enzymes that remove an acetyl group from the histone
protein and prevent gene transcription, have been shown
to induce apoptosis, promote cell differentiation, and
inhibit cancer cell growth (49). HDACi reduce the
expression of homologous recombination genes, such as
BRCA 1 and 2 (50). Additionally, in ovarian cancer cells,
the overexpression of HDAC is associated with cisplatin
resistance (51). In vitro, HDACi have reversed cisplatin
resistance and induced apoptosis (52,53). The inhibitors
result in a depletion of HDAC, which leads to a decreased
expression of chromatin maintenance proteins. Without
these structural anchors, the chromatin’s morphology
transforms into a more receptive conformation, allowing for
chemo-sensitization (54).
Currently available HDACi are vorinostat, belinostat,
and romidepsin. HDACi as single agents for recurrent or
persistent ovarian cancer have shown minimal efficacy. In
a phase II study of 27 women with recurrent or persistent
ovarian or primary peritoneal carcinoma, patients received
vorinostat 400 mg daily and continued until disease
progression or unacceptable toxicity. Of the 24/27 patients
eligible for evaluation, only 1 had a PR, 9 had SD and 14
progressed within 2 months. Toxicity was minimal with 10
patients getting ≥3 cycles of treatment and only two grade
4 AEs (neutropenia and leukopenia) (55). In a phase II
combination study vorinostat was used with paclitaxel and
carboplatin as primary induction therapy in 18 patients with
advanced stage ovarian cancer after cytoreductive surgery.
Patients received a median of six cycles; there were two PRs
and seven CRs. Unfortunately, there were significant AEs,
resulting in early termination of the study. Three patients
had either gastrointestinal perforation or fistula formation
(notably, these patients all had bowel reanastomosis as part
of their initial cytoreductive surgery). There were also
significant hematologic toxicities (56).
In contrast, a combination study of belinostat,
carboplatin, and paclitaxel in a phase I/II study had more
promising results. Belinostat was given at 1,000 mg/m 2
daily for 4 days with carboplatin AUC 5 and paclitaxel
175 mg/m2 on days 3 and 21. Of the 35 heavily pre-treated
patients, 15 patients had a PR and 3 had a CR. The ORR
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was 43% among platinum resistant patients and 63%
among platinum sensitive patients. There were no nonhematologic grade 4 toxicities but several episodes of grade
4 neutropenia (57). The difference in ORR between the
platinum sensitive and resistant groups suggests that further
studies need to separate these subtypes. However, a phase
II study of belinostat with carboplatin (without paclitaxel)
was terminated early for lack of activity (58). It is unclear if
this finding of increased toxicity with vorinostat compared
to belinostat was due to increased total dose, differing
stages of therapy, a specific drug effect, or small sample
sizes. Although current results with HDACi added to
chemotherapy in ovarian cancer have yielded contradictory
data, further investigations of these agents to reverse
platinum resistance are not generating enthusiasm because
of tolerance issues in platinum pretreated patients.
Other agents to reverse platinum and taxane
resistance
Buthionine sulfoximine, an inhibitor of glutathione
synthetase, was studied as a potential agent to reverse
platinum resistance by down regulating intracellular thiols.
However, in spite of strong in vitro data, the complexity of
mechanisms associated with platinum resistance, interest
in the development of buthionine sulfoximine and other
intracellular thiol manipulations have not been pursued
beyond phase I (59-61).
Another potential agent for reversal of platinum resistance has
been bortezomib, presumably by interfering with ubiquination of
copper transporter (CTR) 1, the CTR, which is also responsible
for the influx of cisplatin and carboplatin (62). A phase I by
Aghajanian et al. suggested activity of the combination of
carboplatin and IV bortezomib. Here, the ORR was 47%
with two CR and five PR. The recommended phase II dose
of bortezomib was 1.3 mg/m2 (63). More recently, in a phase I
GOG study by Jandial et al., responses were seen in platinum
resistant patients receiving IP bortezomib and increasing
doses of IP carboplatin. When IP bortezomib was given
before IP cisplatin, platinum accumulation was increased in
peritoneal tumors by 33% (P=0.006) (64). Cyclosporine has
also been used for this purpose, although the mechanism of
potentiation with platinum compounds is unclear (65,66).
Finally, other DNA damaging chemotherapies, such as
topoisomerase I or II inhibitors, may prove to be synergistic
with cisplatin or carboplatin in a schedule dependent manner,
as seen in preclinical studies and in the phase I study of the
combination of topotecan and cisplatin (67). Unfortunately,
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the phase III GOG study 182 used the less toxic but
also less effective schedule of topotecan on days 1-3 and
carboplatin on day 3. There was no difference in PFS or OS
when compared to the standard taxane-platinum doublet (3).
By contrast, an IP schedule in a phase I study of IP cisplatin
50 mg on day 1 and escalating doses of topotecan on days 1-5
resulted in a PFS of 13 months for patients who had minimal
or no disease at the end of induction. Five patients were alive
at 4 years. Even given this considerable activity, these results
have not been studied further (68).
With respect to paclitaxel resistance, the focus has been
on inhibiting P-glycoprotein. P-glycoprotein is an efflux
membrane pump that brings intracellular drugs, including
chemotherapies such as paclitaxel, out of the cell. This process
reduces the drug’s intracellular concentration, and therefore
its effect and toxicity (69). In a phase III study employing
the inhibitor, valspodar (PSC-833) vs. placebo in first-line
treatment of ovarian cancer, no advantage was seen (70).
Targeting the folate receptor
The folate receptor-α (FRA) is present on ovarian cancer but
not in benign ovarian tissues (71,72). The function of this
receptor is unknown as folate transport is mediated primarily
by the highly-affinity reduced folate carrier (RFC). However,
FRA may be a reasonable target for delivery of anticancer
drugs via receptor-mediated endocytosis. The humanized
monoclonal antibody, farletuzumab (MORAb-003), has been
developed as a potential anticancer drug. In a phase I trial of
single agent farletuzumab arm in 25 patients with platinumrefractory or platinum-resistant epithelial ovarian cancer,
farletuzumab was generally safe and well-tolerated. Thirtysix percent of patients had SD but there were no objective
responses (73). In a phase II study, farletuzumab was studied
as a single agent or in combination with carboplatin and a
taxanes in 54 patients with first-relapse, platinum-sensitive
ovarian, fallopian tube, and primary peritoneal cancers.
Patients with asymptomatic CA-125 relapse received single
agent farletuzumab and could receive chemotherapy +
farletuzumab upon single agent progression (n=28). Twentysix subjects who had symptomatic relapse entered on the
combination arm. Farletuzumab was well-tolerated as a
single agent and there was no additional toxicity when it was
combined with chemotherapy. Of 47 patients who ultimately
received farletuzumab with chemotherapy, 80.9% normalized
CA-125 levels. The complete or partial ORR was 75% with
combination therapy (74). The results of this phase II trial
were promising, leading to evaluation in phase III. However,
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a phase III study in platinum-resistant ovarian cancer was
terminated at interim analysis because it did not meet prespecified criteria for continuation after futility analysis (75).
A similar phase III study in platinum-sensitive ovarian cancer
was halted given failure to meet pre-specified criteria for
significant PFS, the study’s primary end point (76,77).
Vintafolide (EC145) is a folate antibody vinca alkaloid drug
conjugate. In a phase II study, 149 patients with platinumresistant ovarian cancer were randomized to pegylated
liposomal doxorubicin (PLD) 50 mg/m2 every 4 weeks with
or without vintafolide at a dose of 2.5 mg intravenously three
times weekly during weeks 1 and 3 on a 4-week cycle. The PFS
was 5.0 months in the combination therapy arm as compared
to 2.7 months in the PLD group (P=0.031). However, when
patients’ tumors were selected for folate receptors with EC20
imaging [a (99m)Tc-based folate peptide chelator that binds
to folate receptor positive cells and tissues, making it useful
for radiodiagnostics], PFS was non-significantly improved in
the folate receptor positive group (median PFS 7.0 months;
HR 0.873; 95% CI, 0.334-2.277; P=0.79) compared to the
non-folate receptor positive group (median PFS 5.4 months;
HR 1.806; 95% CI, 0.369-8.833; P=0.468). There was no
significant difference in AEs (78). A randomized phase III
study of PLD ± vintafolide has completed recruiting and
results are pending (79).
MEK inhibitors
The mitogen activated protein kinase/extracellular signalregulated kinase (MAPK/ERK) pathway is a signal
transduction pathway that regulates cellular growth and
survival. In normal cells, an extracellular ligand is required
to activate this pathway. After initiation, the signal is
potentiated intracellularly via several activating kinases,
communicating with various transcriptional factors
to promote cell growth. However, in malignant cells,
mutations in this pathway lead to constitutive activation
and uninhibited growth. Multiple targets exist within the
pathway, including MEK [also known as mitogen-activated
protein kinase kinase (MAPKK)], which is a tyrosine/
threonine kinase. While MEK inhibitors, such as trametinib,
have seen success in BRAF mutated melanoma, their utility
in other tumors is yet to be proven (80). A phase II study
of single-agent selumetinib, a MEK inhibitor, in lowgrade serous ovarian cancer was performed in 52 patients.
ORR was 15% and an additional 34 patients (65%) had
SD (81). These results demonstrate that MEK inhibition
may have some effect in ovarian cancer. Combination with
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chemotherapy may improve the efficacy of these targeted
agents. However, there is only one pending combination
study of a MEK inhibitor (MEK162) and paclitaxel that
is currently enrolling (82). A trial comparing MEK162 to
chemotherapy of the physicians’ choice in low grade serous
ovarian cancer is also currently recruiting (83).
Methylnaltrexone
Opiate antagonists, specifically methylnaltrexone, have
been shown to inhibit VEGF-induced angiogenesis (84).
In fact, a synergistic effect between methylnaltrexone, a
mu-opioid receptor antagonist, 5-fluorouracil (5-FU), and
bevacizumab has been shown in preclinical models. This
synergy is likely induced by the varied targets of these drugs.
While bevacizumab inhibits VEGF binding to receptors,
5-FU inhibits Akt activation of VEGF, and methylnaltrexone
simulates receptor protein tyrosine phosphatase mu (RPTPµ)
activity that prevents VEGF induced Src activation (85).
A phase I trial of dasatinib, bevacizumab, paclitaxel ±
methylnaltrexone in advanced cancer is ongoing (86). It will
ultimately be interesting to compare methylnaltrexone’s
capacity to inhibit tumor growth.
Conclusions
Given the grim prognosis in ovarian cancer, much effort
has been dedicated to identify targeted therapies that
may improve outcomes in combination with the standard
chemotherapy ‘backbone’ of platinum and taxane agents. In
this review, we discuss the conducted and ongoing studies of
tyrosine kinase inhibitors, Src kinase inhibitors and HDACi.
We also briefly discuss other targets including bortezomib,
the folate receptor, MEK inhibitors, and methylnatrexone.
Clinical trials of these agents have yielded mixed results
ranging from differing efficacy data and issues with drug
tolerance Future clinical trials and studies on drug and
pathway resistance will pave the way to our understanding
and use of these agents in ovarian cancer.
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